Agammaglobulinemia News and Research

RSS

Researchers analyze targets of human T cell recognition against all coronaviruses

Researchers analyzed T cell reactivity against alpha and beta common cold coronaviruses (CoVs) [(CCC)] to inform the development of pan-CoV vaccine concepts.

9 Jan 2023

COVID-19 outcomes among individuals with common variable immunodeficiency

Researchers evaluated the outcomes of COVID-19 in individuals with common variable immunodeficiency.

17 Oct 2022

Scientists show how T cells may help protect against severe COVID

In a recent study published in the Clinical Infectious Diseases journal, the researchers summarized the perspectives and observations on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related adaptive immunity.

25 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Key protein could be a novel target for treatment of patients with B cell signaling deficiencies

The rules to the kids' game "red light, green light" are easy to follow: red always means stop, and green always means go. But now, researchers from Japan have found that a key protein involved in B cell signaling acts as both a red light to signaling in healthy cells and a green light to signaling in immune-deficient cells.

4 Apr 2022

Convalescent plasma in COVID-19 can be effective, especially early in disease

A team of researchers in the United States have conducted an extensive literature review looking at the usage of convalescent plasma from recovered COVID-19 patients to treat those with an impaired immune system. Their study, titled “Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review,” has been released on medRxiv*, the preprint server.

12 Nov 2020

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

2 Jun 2020

COVID-19 and immunodeficiency

COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.

21 Apr 2020

When an insurer balks and treatment stops

Gillen Washington, a student at Northern Arizona University, had been getting medication for an immunodeficiency disease since 2011. But when he went to his clinic in November 2014 for the monthly dose, a nurse told him his insurance company had denied it.

7 Jun 2017

Researchers find method to repair gene mutation causing autoimmune deficiency disease

Researchers at Karolinska Institutet in Sweden have found a method to repair the gene mutation causing agammaglobulinemia, an autoimmune deficiency disease that almost exclusively affects boys and in which the body lacks the ability to produce immunoglobulins (gamma globulin).

14 Aug 2014

Scientists solve a decades-long mystery of cell biology

A team led by scientists at The Scripps Research Institute has identified a long-sought protein that facilitates one of the most basic functions of cells: regulating their volume to keep from swelling excessively.

11 Apr 2014

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

X-linked agammaglobulinemia

Individuals who have a rare genetic immune system disorder that prevents them from making antibodies nevertheless appear to be moderately healthy and lead productive lives, according to results of a study by investigators at St. Jude Children's Research Hospital.

18 Jan 2006